EUCTR2012-003244-76-AT
Active, not recruiting
Phase 1
Feasibility of intraoperative hyperthermic intraperitoneal chemotherapy with carboplatin and paclitaxel in patients with advanced epithelial ovarian cancer – a combined phase I / II trial - HIPEC-Ovar
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Otherwise treatment-naive patients with epithelial ovarian cancer, FIGO III - IVa
- Sponsor
- Medical University of Vienna
- Enrollment
- 20
- Status
- Active, not recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age \>\=18 years and \<\=75 years, epithelial ovarian cancer FIGO III \- IVa, visible tumor rest at the end of surgery \<0,5cm, signed informed consent, no medical circumstances that prohibit the performance of a HIPEC
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 15
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 5
Exclusion Criteria
- •Age \< 18 years or \> 75 years, other histology than epithelial ovarian cancer or epithelial ovarian cancer with FIGO other than III \- IVa, visible tumor rest at the end of surgery \>\=0,5cm, no signed informed consent, medical circumstances that prohibit the performance of a HIPEC
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Feasibility study of hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with stage III or only pleural stage IV ovarian carcinoma in first line therapy. - HIPEC-ovarian carcinomaInclusion criteria :1. Histologically confirmed ovarian carcinoma or primary peritoneal carcinoma or Fallopian tube carcinoma.2. FIGO stage III disease or only pleural stage IV disease3. Age less than 65 years4. ECOG performance status 0-1.5. Adequate bone marrow, hepatic and renal functions.6. No serious cardiac or respiratory illnessEUCTR2009-009467-59-BEInstitut Jules Bordet
Completed
Not Applicable
Safety and efficacy of heated chemotherapy given during surgery in management of gall bladder cancerHealth Condition 1: null- Carcinoma gall bladderCTRI/2018/02/011879I45
Active, not recruiting
Phase 1
Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery in gastric carcinoma at high risk of peritoneal carcinomatosis.Patients with gastric carcinoma at high risk of developing peritoneal carcinomatosis, suitable to radical surgery.MedDRA version: 21.0Level: LLTClassification code 10007350Term: Carcinoma gastricSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-001478-27-ITAssociazione Chirurghi Ospedalieri Italiani240
Active, not recruiting
Phase 1
Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy versus standard surgery in colorectal carcinoma at high risk of peritoneal carcinomatosispatients with colorectal carcinoma at high risk peritoneal carcinomatosisMedDRA version: 21.1Level: PTClassification code 10061045Term: Colon neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-001437-14-ITAssociazione Chirurghi Ospedalieri Italiani330
Active, not recruiting
Not Applicable
Surgery plus intraperitoneal Hypertermic chemotherapy in platinum-sensitive patients with ovarian cancer recurrence after 12 months. Phase II studyRecurrent ovarian cancerMedDRA version: 6.1Level: PTClassification code 10033128EUCTR2005-000927-41-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI